About Us


Timothy M. Salmon, JD

Co-founder, President & Chief Executive Officer

Tim is a registered U.S. patent attorney with over ten years of experience in patent prosecution, litigation, licensing and due diligence.  In addition to working for law firms in New York City, Tim was in-house patent counsel at Sanofi for several years, supporting Sanofi’s drug/device combination product development, academic collaborations, patent litigations and business development.  Tim has a Bachelor of Science in Biomedical Engineering from the University of Rochester and a Juris Doctor from St. John’s University School of Law.

Daniel Mitry, JD

Co-founder, VP of Business Development

Daniel is a registered U.S. patent attorney with extensive experience in patent litigation and licensing. While working at prestigious law firms and as Senior IP Counsel at one of the largest financial software and media companies in the world, Daniel has worked on numerous IP-based business transactions. Daniel has a Bachelor of Science in Computer Science from the University of Maryland and a Juris Doctor from Brooklyn Law School.

Anna Bunin, PhD

Anna is an immunologist with extensive knowledge of cellular and molecular immunology. Anna has a BS in Cell Biology and Genetics, With Honors, Magna Cum Laude, from the University of Minnesota-Twin Cities and her PhD in Immunology from Emory University. Anna worked for several years at Columbia University as a Fellow and Research Scientist, focusing on innate immune responses to DNA/RNA viruses and celiac disease. Upon leaving Columbia, Anna has worked at several immunotherapy companies. Anna has an excellent scientific track record as demonstrated by publications in top-tier scientific journals.

Advisory Board

Debasish Roychowdhury, MD

Debasish Roychowdhury, MD is a medical oncologist with over 15 years of comprehensive pharmaceutical industry and senior management experience and over 14 years of patient care, academic research and teaching experience. Dr. Roychowdhury is a leader in the pharmaceutical industry across multiple functional and cross-functional areas, regions and matrices, including – all stages of R&D, regulatory, commercial operations and medical affairs, market access, business development and alliance management. Dr. Roychowdhury was involved in nine new drug approvals in the US and EU and other markets and numerous supplemental approvals.

Dr. Roychowdhury is currently the Chief Medical Officer for Partner Therapeutics, Inc., a biotechnology company focused on cancer treatments. He was one of the founding members of the Seragon Clinical and Scientific Advisory Board and was the company’s Chief Medical Officer where he played a key role in the development and advancement of Seragon’s selective estrogen receptor degrader (SERD) platform for breast cancer and other hormone-driven cancers until the company was acquired by Roche in August 2014.

Prior to Seragon, Dr. Roychowdhury was the Senior Vice President and Head of the Global Oncology Division at Sanofi until November 2013. Prior to that, he served as the Vice President for Clinical Development at GlaxoSmithKline and directed the Oncology global regulatory group at Eli Lilly and Company. Prior to his role in industry, he served as faculty member at the University of Cincinnati. He trained at the All India Institute of Medical Sciences and University of California, San Francisco. He is a member of the Board of Directors for Partner Therapeutics, Lytix Biopharma AS, Celyad S.A., and Fund+, a life sciences investment fund.

Professor Joachim Fensterle, PhD

Prof. Fensterle began his studies in biotechnology at the Technical University of Braunschweig. After his undergraduate studies, he moved to a French “Grand Ecole”, the École Supérieure de Biotechnologie (ESBS) in Strasbourg. He completed his immunology / infection biology thesis in the research department of Chiron-Biocine in Siena / Italy.

His passion for the molecular interaction of microbial pathogens with the host organism and the resulting targeted attacks by the immune system then led him to a doctorate at the Max Planck Institute for Infection Biology in Berlin. There he worked among others with various bacterial pathogens such as Salmonella, Listeria or the tuberculosis pathogen Mycobacterium tuberculosis.

Shortly after receiving his doctorate in 2000, Prof. Fensterle moved to the Institute for Medical Radiation Science and Cell Research at the University of Würzburg as head of the working group “Bacterial Tumor Therapy.” The aim here was to exploit the infection biological arsenal of microorganisms specifically for tumor therapy. Among other things, the team succeeded in modifying a salmonella strain in such a way that it can in principle be used as a vaccine against prostate cancer. This work culminated in the spin-off of a GmbH, which led Prof. Fensterle as a managing partner, in addition to his activity as an assistant at the university, temporarily led. A selection of his works can be found here .

The international, publicly traded pharmaceutical company Æterna Zentaris became aware in 2005 and took over the project. He also joined the company as Head of Vaccine Development / Business Development. In addition to his work in business development, he was responsible for developing the clinical maturity project there, which included in particular the establishment of industrial testing and production processes.

Prof. Fensterle teaches biotechnology and bioengineering at Rhine-Waal University of Applied Sciences in Kleve, Germany.

Anna Ferrari, MD

Dr. Ferrari is a medical oncologist and clinical researcher dedicated to prostate cancer research. Her experience includes clinical practice and basic laboratory science investigations geared towards preclinical testing for clinical trial development in Prostate Cancer. Dr. Ferrari joined Rutgers Cancer Institute of New Jersey as the Director of the Genitourinary (GU) Cancer Program and Professor of Medicine. Previously, she served as Co-Director of Genitourinary (GU) Program for NYU Perlmutter Cancer Center, and prior to that spent several years at Mount Sinai School of Medicine, serving as Director of the Genitourinary Cancer Program.

As a member of the Genitourinary Committee and Prostate Cancer Clinical Trials Consortium, Dr. Ferrari helps develop clinical trials for prostate cancer on a national level. For many years she played a major role in the clinical trials that lead to the approval of Provenge®, the first FDA approved vaccine for treatment of prostate cancer. Dr. Ferrari also currently active in the development of new agents and vaccines that are highly promising for prostate cancer patients.

As part of the collaborate care offered at Rutgers Cancer Institute of New Jersey, Dr. Ferrari works with multi-discipline experts in the Prostate Cancer and Urology Oncology Programs, which include radiation and surgical oncologists, nurses and social workers. Dr. Ferrari provides patients with a comprehensive evaluation, educating them about their disease and treatment options so they can make informed decisions about their care.  Additionally, she is a strong supporter of patient support groups and lectures regularly to help men understand the prostate cancer spectrum of treatment options and choices.